CA
NZ
UK
AU
IND
US
STERIS Irish FinCo Unlimited Company filed a free writing prospectus on November 9, 2026, disclosing the pricing terms for two tranches of senior notes totaling $1,500,000,000, with settlement expected on November 24, 2026.
The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC filed a joint Schedule 13G with the SEC on November 9, 2026, disclosing beneficial ownership of Class A ordinary shares of Alpex Acquisition Corporation as of September 30, 2026.
The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC filed an amended Schedule 13G with the SEC on November 9, 2026, disclosing beneficial ownership of common stock in People Incorporated as of September 30, 2026.
The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC filed an amended Schedule 13G with the SEC on October 8, 2026, disclosing beneficial ownership of approximately 4.3% of NETSTREIT Corp.'s common stock as of September 30, 2026.
The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC filed an amended beneficial ownership statement with the SEC on November 9, 2026, reporting zero beneficial ownership of ordinary shares of TNL Mediagene as of September 30, 2026.
The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC filed a joint Schedule 13G with the SEC on November 9, 2026, disclosing beneficial ownership of common stock in Pacific Biosciences of California, Inc. as of September 30, 2026.
The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC filed a joint Schedule 13G with the SEC on November 9, 2026, disclosing beneficial ownership of approximately 5.9% of Oxford Industries, Inc. common stock as of September 30, 2026.
The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC filed a joint Schedule 13G with the SEC on November 9, 2026, disclosing beneficial ownership of ordinary shares of Range Capital Acquisition Corp as of September 30, 2026.
GS Finance Corp. filed a Free Writing Prospectus on November 9, 2026, disclosing terms for Market Linked Securities that are autocallable with a fixed percentage buffered downside, linked to the EURO STOXX 50 Index and due November 26, 2029.
The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC filed a joint Schedule 13G with the SEC on November 9, 2026, disclosing beneficial ownership of approximately 5.9% of Tandem Diabetes Care, Inc. common stock as of September 30, 2026.
Please wait processing your request...